Our Pipeline
EstryX Pharma is focused on two advanced projects
Optimization of a novel
Dual Aromatase-Sulfatase Inhibitor (DASI)
Key experiments that will generate the necessary IP basis to underpin moving
STX140 into clinical development
DASI
These “first-in-class” orally active agents combine irreversible inhibition of steroid sulfatase with reversible inhibition of aromatase. Blocking both enzymes in a dual-targeting fashion will completely starve estrogen-dependent tumours of 17β-estradiol, conferring enhanced properties over pure aromatase inhibitors resistance to which is a significant issue. The Company’s IP assets cover both highly potent lead candidates as well as DASIs with excellent preclinical profiles backed by an extensive data package. Optimal ‘hybrid’ DASI’s are also planned. It is envisaged that our eventual clinical partner will advance development initially for treatment, but also ultimately for long-term preventative use.
STX140
This agent has activity as an orally active multi-targeting drug, as a steroid sulfatase inhibitor (STSi), carbonic anhydrase IX (CAIX) inhibitor, microtubule disruptor and angiogenesis inhibitor appropriate for a broad range of tumour types and also has a full preclinical data package. It functions primarily as an irreversible STSi, with several other complementary activities that can be clinically titrated in for optimal efficacy. Three distinct strategies of experiments are currently commencing to generate long patent term IP cover over STX140, both per se and as a novel modified release oral formulation. On success, EstryX envisages advancing STX140 to clinical proof of concept before partnering generating optimal value for nearly 20 years involvement in this area.
